文献速递消化系统肿瘤

ADI-PEG 20联合最佳支持治疗用于晚期肝细胞癌二线治疗的III期随机研究

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.
PubMed 文献 · Ann Oncol · 2018-01-01

这项III期随机研究纳入635例既往接受过系统治疗的晚期肝细胞癌患者,按2:1随机接受ADI-PEG 20(18 mg/m²)或安慰剂每周肌内注射。主要终点总生存期在两组间无差异(7.8个月对7.4个月,P=0.88,HR=1.02),无进展生存期亦无差异(2.6个月对2.6个月,P=0.07,HR=1.17);ADI-PEG 20单药耐受性良好,但未在二线治疗中显示生存获益。

要点

  • ADI-PEG 20单药在晚期HCC二线治疗未改善总生存期(HR=1.02,P=0.88)。
  • 无进展生存期两组均为2.6个月(HR=1.17,P=0.07),无显著差异。
  • 3级疲劳和食欲下降发生率低于5%,≥3级过敏反应仅2例。

核心结论

  • ADI-PEG 20单药在晚期肝细胞癌二线治疗中未显示总生存期获益,但耐受性良好。

研究设计与样本

  • III期随机对照研究,纳入635例组织学确诊的晚期肝细胞癌患者,Child-Pugh分期至B7,既往接受过系统治疗。
  • 患者按2:1随机接受ADI-PEG 20 18 mg/m²或安慰剂每周肌内注射,主要终点为总生存期。

主要发现

  • ADI-PEG 20组中位总生存期7.8个月,安慰剂组7.4个月(P=0.88,HR=1.02)。
  • 中位无进展生存期两组均为2.6个月(P=0.07,HR=1.17)。
  • 3级疲劳和食欲下降发生率低于5%,ADI-PEG 20组有2例≥3级过敏反应。
  • 治疗结束后30天内死亡率ADI-PEG 20组为15.2%,安慰剂组为10.4%,均与治疗无关。
  • 事后分析显示,第4、8、12、16周精氨酸评估中,精氨酸耗竭时间更长者总生存期有改善趋势。

关键数值与推荐

  • 入组患者中位年龄61岁,82%为男性,60%为亚洲人,52%为乙型肝炎,26%为丙型肝炎,76%为IV期,91%为Child-Pugh A级。
  • 70%患者在索拉非尼治疗中进展,16%对索拉非尼不耐受。

临床怎么用

  • ADI-PEG 20单药不推荐用于晚期肝细胞癌二线治疗。
  • 精氨酸耗竭时间更长者总生存期有改善趋势,提示需探索增强持续精氨酸耗竭及协同作用的策略。

局限性

  • 事后分析的证据强度有限,精氨酸耗竭与生存改善的趋势需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Arginine depletion is a putative target in hepatocellular carcinoma (HCC). HCC often lacks argininosuccinate synthetase, a citrulline to arginine-repleting enzyme. ADI-PEG 20 is a cloned arginine degrading enzyme-arginine deiminase-conjugated with polyethylene glycol. The goal of this study was to evaluate this agent as a potential novel therapeutic for HCC after first line systemic therapy. METHODS AND PATIENTS: Patients with histologically proven advanced HCC and Child-Pugh up to B7 with prior systemic therapy, were randomized 2 : 1 to ADI-PEG 20 18 mg/m2 versus placebo intramuscular injection weekly. The primary end point was overall survival (OS), with 93% power to detect a 4-5.6 months increase in median OS (one-sided α = 0.025). Secondary end points included progression-free survival, safety, and arginine correlatives. RESULTS: A total of 635 patients were enrolled: median age 61, 82% male, 60% Asian, 52% hepatitis B, 26% hepatitis C, 76% stage IV, 91% Child-Pugh A, 70% progressed on sorafenib and 16% were intolerant. Median OS was 7.8 months for ADI-PEG 20 versus 7.4 for placebo (P = 0.88, HR = 1.02) and median progression-free survival 2.6 months versus 2.6 (P = 0.07, HR = 1.17). Grade 3 fatigue and decreased appetite occurred in <5% of patients. Two patients on ADI-PEG 20 had ≥grade 3 anaphylactic reaction. Death rate within 30 days of end of treatment was 15.2% on ADI-PEG 20 versus 10.4% on placebo, none related to therapy. Post hoc analyses of arginine assessment at 4, 8, 12 and 16 weeks, demonstrated a trend of improved OS for those with more prolonged arginine depletion. CONCLUSION: ADI-PEG 20 monotherapy did not demonstrate an OS benefit in second line setting for HCC. It was well tolerated. Strategies to enhance prolonged arginine depletion and synergize the effect of ADI-PEG 20 are underway. CLINICAL TRIAL NUMBER: www.clinicaltrials.gov (NCT 01287585).

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Abou-Alfa GK, Qin S, Ryoo BY, et al. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Ann Oncol. 2018. PMID: 29659672. doi:10.1093/annonc/mdy101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。